anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A computer-implemented method for monitoring disease vectors is disclosed. A vector sensor obtains vector data relating to disease vectors in a monitored area. An environmental data obtaining component obtains environmental data relating to the monitored area. Based on at least one of the vector data and the environmental data, a population characteristic component may estimate or determine a vector population characteristic associated with the monitored area. A structural data obtaining component may obtain structural data relating to the monitored area. A vector travel estimation component may estimate or determine a vector travel characteristic. The vector characteristic may be indicative of predicted disease vector movement from outdoors to indoors in the monitored area and may allow for or facilitate a vector control action based at least partially on the vector travel characteristic. A device and a system for monitoring disease vectors are also disclosed.
Efforts at treating radiation-induced cognitive and neuropsychiatric declines with medications have shown only minimal preliminary cognitive benefit and do not affect quality of life (QOL). Given the structural and functional brain alterations associated with WBRT, preventing rather than treating these radiation-induced changes may produce more favorable outcomes. Innovative radiotherapy techniques can limit the dose of radiation applied to specific brain structures without compromising tumor coverage. In this light, Radiation Therapy Oncology Group (RTOG) recently published a study evaluating the hippocampal avoidance whole brain radiation therapy (WBRT) in patients with brain metastases. They suggest potential preservation of cognitive function with this approach with no perceived detriment in survival. This concept is currently undergoing investigation in a definitive randomized controlled study (NRG-CC003) in patients receiving prophylactic cranial irradiation for small cell lung cancer. However, no other studies to date have prospectively evaluated avoidance of other particularly sensitive brain regions.

One brain region that has received little attention in the radiotherapy literature is the corpus callosum. The genu of the corpus callosum contains thin, densely packed neural fibers that primarily connect the prefrontal association areas and the anterior inferior parietal regions of the brain. Damage or thinning of the genu is associated with reduced functioning on tests of executive functioning, attention, working memory, processing speed, verbal fluency and memory in a variety of healthy and patient groups including aging, cerebral small vessel disease, traumatic brain injury, multiple sclerosis , human immunodeficiency virus, mild cognitive impairment secondary to Parkinson's disease, and euthymic bipolar disorder. The limited existing data in adults receiving WBRT for brain metastases suggest that they also perceive progressive declines in motivation following treatment. Given its apparent involvement in a wide range of cognitive processes, the genu of the corpus callosum is an excellent candidate for sparing in WBRT. This relatively small area has the potential to preserve cognitive functioning across several domains if guarded from the damaging effects of radiation. In this study patients will receive the standard whole brain radiation dose of 3000 centigray (cGy) in 10 fractions, but intensity modulated radiation therapy will be utilized to limit radiation dose to the genu of the corpus callosum. Patients will undergo cognitive testing at baseline and at 4-, 6- and 12-months following completion of brain radiation to evaluate the study hypothesis.
<P>PROBLEM TO BE SOLVED: To provide a means for improving the fragility of a coating film formed from an external preparation for skin and not originated from an aqueous component in the water-in-oil type external preparation for the skin.  <P>SOLUTION: This water-in-oil type external preparation for the skin is characterized by containing powder having a coating layer containing hydroxyapatite in an amount of 0.01 to 5 mass%. It is preferable to contain an organic modified clay mineral as an emulsifier. It is preferable that the organic modified clay mineral is hectorite modified with dimethyldistearyl ammonium chloride. In addition, it is preferable that a dimer acid diester and an amino group-silicone are contained.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Use of estradiol valerate with 17alpha -cyanomethyl-17-beta -hydroxyestra-4,9-diene-3-one for producing a multi-phase combination preparation for the oral therapy of the dysfunctional uterine bleeding in the form of oral contraceptives. The combination of estradiol valerate with dienogest comprises a first phase consisting of 2 daily dose units of estradiol valerate, a second phase consisting of 2 groups of daily dose units of the combination, where the first group contains 5 daily dose units and the second group contains 17 daily dose, and a third phase consisting of 2 daily dose units. Use of estradiol valerate with 17alpha -cyanomethyl-17-beta -hydroxyestra-4,9-diene-3-one (dienogest) for producing a multi-phase combination preparation for the oral therapy of the dysfunctional uterine bleeding, in the form of oral contraceptives. The combination of estradiol valerate with dienogest comprises a first phase consisting of 2 daily dose units of estradiol valerate at 3 mg, a second phase consisting of 2 groups of daily dose units, where the first group contains 5 daily dose units of a combination of 2 mg estradiol valerate and 2 mg of dienogest and the second group contains 17 daily dose units consisting of a combination of 2 mg of estradiol valerate and 3 mg of dienogest, a third phase consisting of 2 daily dose units having 1 mg of estradiol valerate and an additional phase consisting of 2 daily dose units on a pharmaceutically harmless placebo. The entire daily dose units of the multi-phase combination corresponds to 28 days. ACTIVITY : Contraceptive; Gynecological. MECHANISM OF ACTION : None given.
Patients started on Peritoneal Dialysis will have Cardiac MRI 3 - Without Gadolinium Contrast after 6 months of therapy. Patients will have Peripheral Whole Blood Samples taken at defined intervals.
Vaccination is the principal strategy for primary prevention of infection by Human Papilloma Virus (HPV), which causes different pathological conditions, up to cancer, in both males and females. However, to date, knowledge among adolescents and their parents about the HPV vaccine is still low. The aim of this quasi-experimental, multicenter study is to assess the effectiveness of a digital educational intervention, conducted by a multidisciplinary health-care team including a Community Nurse, to increase adolescents' HPV vaccination uptake, their knowledge, self-efficacy, feelings and involvement in HPV vaccine decision-making, and parents' vaccination hesitancy. The study will be carried out among a population of students (and their parents), aged between 11 and 13, at secondary schools in Italy. Validated questionnaires will be administered to both students and parents at baseline (T0) and 3 months after a digital educational intervention (T1). The findings may be useful in evaluating and deepening a methodology for designing and implementing educational interventions, embedded in the school setting, that could promote the achievement of outcomes within the broader process of youth's health promotion.
Three weeks prior to the target quit date, participants will switch to smoking very low nicotine content cigarettes and wear a 21 mg/d nicotine patch. During the 3-week, pre-quit period, participants will undergo six, 60 minute sessions during which they will view smoking-related environments and smoke their assigned cigarettes. Following the quit date, participants will quit smoking and wear the nicotine patch for 10 weeks.
Ulsan University Hospital-Health Screening Cohort is a prospective cohort of participants who participated in general health screening programs at the Health Promotion Center of Ulsan University Hospital (Ulsan, South Korea). This cohort includes health screening participants aged 19 years and older from community and workplace. The purpose of this cohort is to offer relevant and useful data on health risk factors in the field of non-communicable diseases such as cardiovascular disease and malignancy.
Methods for labeling mannose lectins on the surface of mammalian sperm cells are described, and methods of categorizing and quantifying the numbers of cells exhibiting particular labeling patterns are also provided. These methods provide ways of detecting whether or not a mammalian male patient has mannose lectin-correlated infertility, which is determined on the basis of the relative numbers of sperm cells labeled with particular labeling patterns. Methods for detecting capacitation-induced changes in the distribution of mannose lectins on mammalian sperm cells are also provided, and these methods can also be used to detect whether or not a mammalian male patient has mannose lectin-correlated infertility, on the basis of the comparative relative labeling in capacitated and non-capacitated sperm cell samples. In addition, the various methods are shown to be useful for determining whether chemical compounds have effects on mammalian sperm cell surface lectin distribution or acrosomal states. For example, they can be used to evaluate the effects of environmental or occupational toxin exposure, and to evaluate the effects of potential or existing drugs, which effects may correlate with changes in sperm fertility. A kit for carrying out the foregoing methods is also provided.
PCT No. PCT/FR94/01251 Sec. 371 Date Aug. 1, 1996 Sec. 102(e) Date Aug. 1, 1996 PCT Filed Oct. 27, 1994 PCT Pub. No. WO95/11665 PCT Pub. Date May 4, 1995A dosage form for orally administering chemical or medicinal substances such as vitamins, trace elements, amino acids, nutritive substances, vaccines, etc., to domestic or wild animals, and a method for preparing same, are disclosed. Said dosage form includes: a porous water-soluble central core containing binders selected from polypeptides, polysaccharides, polymers and colloids, and/or diluents selected from polyols, metal oxides, carbonates, phosphates and microcrystalline cellulose, and an effective amount of at least one bioactive substance; and a palatable hydrophobic outer layer containing at least one lipid substance selected from fatty alcohols, fatty acids, glycerol esters, hydrogenated oils, waxes, paraffin, lanolin, coconut oil and fatty acid salts; a polymeric agent for modulating the disintegration and adhesion of said outer layer, and natural or synthetic palatable substances.
Dasatinib is one of the second generation tyrosine kinase inhibitors (TKI) which is approved for the treatment of patients with chronic phase CML (CP-CML) both in the front line and in the second line setting. Pleural effusion (PE) is a unique toxicity associated with dasatinib use. Our aim was to study the incidence of pleural effusion in our cohort of patients who were treated with dasatinib for CP-CML and the safety upon TKI switch. A total of 390 patients were treated with dasatinib during their course of treatment for CP-CML. A total of 69 patients (17.6%) developed any grade of PE. About 33 (48%) patients developed CTCAE grade 2 PE, 34 (49%) grade 3 and only 1 patient developed grade 4 PE. Recurrence of PE was observed in 34 (49%) patients. While only 12 patients (17.3%) continued using dasatinib after development of PE, dasatinib was discontinued in the other 57 patients. Therapy was switched to bosutinib in 13 patients out of which 6 (46%) patients re-developed PE. While only 12.5% patients developed re-accumulation of pleural fluid in patients switched to imatinib, none of the patients switched to nilotinib re-developed PE. A change in TKI to bosutinib was associated with a 46% risk of recurrence of PE in patients who develop PE on dasatinib for the treatment of CP-CML. The incidence of recurrent PE was markedly lower in patient switched to imatinib or nilotinib.
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Monitor patients for respiratory depression and sedation [see Warnings and Precautions (5.2) and Drug Interactions (7.1)].

Titrate the dose of midazolam in sodium chloride injection when administered with opioid analgesics and sedative- hypnotics to the desired clinical response.

Continuously monitor sedated patients for hypotension, airway obstruction, hypoventilation, apnea, and oxygen desaturation. These cardiorespiratory effects may be more likely to occur in patients with obstructive sleep apnea, the elderly, and ASA-PS III or IV patients.

Concomitant use of barbiturates, alcohol, or other central nervous system depressants may increase the risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect. Narcotic premedication also depresses the ventilatory response to carbon dioxide stimulation.
PURPOSE:To rapidly perform the examination of an object to be examined, by recording the discrimination data relating to the object to be examined and an image on a recording medium along with digital image data and converting the image data to analogue data when said image data are read from the recording medium to output the same as sound. CONSTITUTION:When the image of the region to be diagnosed of an object to be examined is taken by an imaging apparatus 1, the discrimination data or comments relating to the object to be examined and an image are inputted as sounds. By this method, the sound data of the discrimination data are recorded on the recording medium of a recording apparatus 3 along with the image data of a medical image. Next, in order to read the image thus recorded to perform diagnosis, the image data and the sound data are respectively read from the recording apparatus 3 at first and sound data is read from a sound memory 7 to be converted to an analogue signal by a D/A converter 8. This analogue signal is outputted as the sound showing the discrimination data or the like from a speaker 9. By this method, all the discrimination data can be heard as a sound by the sound output from the speaker 9 while the medical image displayed on the picture of a display apparatus 4 is observed.
Double Flap Technique (Group A) A 360-degree peritomy will be performed to expose the underlying sclera. Following evisceration of the ocular contents, careful hemostasis will be achieved. Two muscular-tendinous flaps will be developed from the horizontal rectus muscles. These flaps will be dissected under minimal tension to preserve their vascular supply. The prepared flaps will be draped over the implant in a manner that the edges slightly overlap, ensuring complete coverage. The flaps will be sutured together using silk sutures, securing the implant in place.The conjunctiva will be meticulously closed over the muscle flaps with continuous absorbable sutures to enhance the healing process and minimize postoperative discomfort.
Tegavivint will be administered IV over 4 hours on days 1, 8, and 15 of each cycle. Administer D5W flush after completion of each tegavivint infusion. Treatment repeats every 28 days for up to 26 cycles or 24 months in the absence of disease progression or unacceptable toxicity. Drug doses should be adjusted based on the weight (height and BSA will also be captured) measured within 7 days prior to the beginning of each cycle. The starting dose will be 5 mg/kg with dose levels for subsequent cohorts increasing to 6.5 mg/kg and 8 mg/kg if excessive toxicity does not occur. If the MTD has been exceeded at the first dose level, then the subsequent cohort of patients will be treated at a dose of 4 mg/kg. Patients undergo an x-ray at baseline, after cycle 1, and then every 3 cycles while on treatment and DEXA scan at baseline and every 6 cycles while on treatment, then at 12 months, 24 months, and annually up to 60 months following end of therapy.
PURPOSE: A composition and a functional food containing Olibanum ethanol extract is provided to induce cancer cell apoptosis and to prevent and treat brain cancer. CONSTITUTION: A composition for preventing and treating brain cancer contains Olibanum ethanol extract preparing at 50 Deg. C. for 24 hours as an active ingredient. The ethanol is 95% ethanol. The composition contains pharmaceutically acceptable carriers or diluents. A functional food for preventing brain cancer contains the extract containing sitologically acceptable food additive. 94% of U-87 MG brain cancer cells are killed by 100 ug/ml of the extract. The EC50(half maximal effective concentration) is 57.798 ug/ml.
<P>PROBLEM TO BE SOLVED: To provide a medical information display device for enabling a patient to easily understand medical information regardless of the use language or age of a patient or the like.  <P>SOLUTION: A user inputs the name of a patient or patient ID by an image diagnostic device 100. A patient information obtaining part 14A obtains personal information such as the age and nationality of the patient from a patient information table 22 of an image server 2 based on the patient ID. An image information obtaining part 13A obtains image data obtained by performing the diagnosis and photographing of the patient by the user, and makes a display part display the image data. The user inputs the characters or symbols of Japanese by referring to an image, and the characters or symbols of Japanese as well as the image are displayed at the user's desired position. An input information conversion part 17A refers to a language dictionary table 31 of a conversion table database 3 based on the obtained patient's nationality. Then, an input information conversion part 17A converts (translates) the characters of Japanese recognized by the character recognition part 18A into language to be used in the county of the patient. A control part 10A makes the display part display the translated characters just below the position of the input characters prior to translation.  <P>COPYRIGHT: (C)2011,JPO&INPIT
1449317 Dentifrice BEECHAM GROUP Ltd 23 Jan 1975 [8 Feb 1974] 5983/74 Heading A5B Dentifrice compositions containing an abrasive having its abrasivity reduced by the addition of certain particulate materials comprise a cleaning agent which consists of from 75-99.9% by weight of particulate calcium carbonate and from 0.1-25% by weight of a water insoluble particulate polymeric material which is (a) less abrasive and (b) of lower average density than the calcium carbonate e.g. polymethyl methacrylate, polyisobutyl methacrylate, cellulose acetate and butyrate, polyamides, polyethylene, polypropylene, polystyrene, polyvinyl chloride and co-polymers of polyvinylchloride and polyvinyl alcohol. The polymeric material may be in the form of particles which are hollow or have cavities. The compositions may be in the from of pastes, liquids, gels, ointments, emulsions, powders, tablets, dragees or chewing gum and may additionally contain a detergent e.g. sodium lauryl sulphate, sodium N-lauroyl sarcosinate and ricinoleate and sulphoricinoleate derivatives; humectant e.g. glycerol, sorbitol, propanediol and/or butanediol; binding agent e.g. gum tragacanth, sodium carraglcenate, carboxymethyl cellulose, cellulose ethers, polyacrylic acid and polyvinylpyrrolidone; flavouring agent e.g. peppermint or spearmint oil, menthol, oils of clove, wintergreen, eucalyptus, aniseed, rose, lavender, saccharin and sodium cyclamate; preservatives e.g. p-hydroxybenzoic acid esters and hexachlorophene; colour e.g. dyestuffs, bleaches, optical brighteners such as sodium perborate, magnesium peroxide, hydrogen peroxide-urea compounds; and/or an ionic fluoride or fluorophosphate compound e.g. stannous fluoride, ammonium fluoride or sodium monofluorophosphate.
[GB1449317A]
According to one aspect of the present invention, an artificial intelligence-based brain information providing method includes: a first step in which a brain signal stimulation part stimulates the brain of a user; a second step in which a brain signal measurement part collects a signal related with the brain of the user based on the stimulation; and a third step in which a diagnosis part determines a brain condition of the user, based on the collected signal. In the second step, the signal collection operation of the brain signal measurement part is performed in a state in which the user is moving. In the third step, the diagnosis part determines the brain condition of the user, based on at least one brain vitalization area extracted consecutively for a predetermined period. Between the second-2 step and the third step, the method also includes a second-4 step in which an image collection part collects medical images related with the user, and a user data collection part collects body information related with the user. In the third step, the diagnosis part determines the brain condition of the user using the at least one brain vitalization area, the body information related with the user, and the medical images related with the user. In the third step, the diagnosis part determines a brain disease of the user, and the brain disease includes dementia, mild cognitive impairment (MCI), Parkinson's disease, depression, a stroke, epilepsy, and a brain tumor, and a developmental disorder. After the third step, the method can also include a fourth step in which a management part provides information for improving the brain condition of the user in response to the brain condition of the user determined by the diagnosis part. Therefore, the present invention is capable of helping to develop the brain in a healthy manner.
Intervention 4: Standard treatment. It is defined as treatment aimed to control symptoms including fever and pain, multiple organ failure related to the acute infection including respiratory support (oxygen, positive end-expiration pressure with external devices or invasive ventilatory support), cardiovascular, renal, haematological or coagulation, or co-infection with bacterial or mycotic organisms, standard care to prevent pressure ulcers or other care required by the patient, might include Dexamethasone. No viral therapies are included.
Arm A will consist of subjects with prior whole pelvic radiation. Subjects will receive weekly CCI-779 and topotecan at the assigned dose.
A substance suitable for the treatment of malignant tumours such as cancer, is prepared by treating (a) female animal blood taken during a period of from a few days before to a few days after delivery or taken during the first few days of menstruation, or (b) colostrum, undiluted with water, with an excess of a substantially non-aqueous water-miscible solvent to precipitate protein bodies containing the active substance, separating the solvent from and drying the precipitate and dispersing the dried precipitate in a neutral to slightly alkaline physiological solution.  In the example, human colostrum is centrifuged to remove fat, coated to 0 DEG  C. and allowed to stand.  Absolute alcohol at 0 DEG  C. is added slowly over 10 minutes, the mixture allowed to stand at room temperature for 50 minutes and then cooled to 0 DEG  C.  The precipitate is centrifuged and alcohol removed in vacuo at 45 DEG  C.  The precipitate is eluted with physiological saline solution containing disodium phosphate, stirred with bolus alba and centrifuged.  The liquid obtained contains the active principle and can be injected, taken orally, or freeze dried to form a powder which is mixed with sterile water as required.  Kaolin or fuller's earth may be used in place of bolus alba.  The non-aqueous solvent may be absolute ethyl alcohol or acetone.  Reference is made to the Cancer Act 1939.